Atticus Pharma

Atticus Pharma

生物技术研究

Greenville,South Carolina 80 位关注者

Better topical drugs through sustained-release delivery

关于我们

Atticus Pharma has generated a drug pipeline on the strength of an innovative topical drug-delivery platform originally developed at Albert Einstein College of Medicine. The Z-pod? encapsulation technology platform provides sustained release of an API of choice, providing more physiologic dosing and thereby enhancing bioavailability. The technology is highly efficient, scalable, and cost-effective. The lead program is anandamide-loaded Z-pods for the treatment of lupus lesions, an area of high unmet need. The second program is Y200-loaded Z-pods for the treatment of hair loss (androgenic alopecia).

网站
www.atticuspharma.com
所属行业
生物技术研究
规模
2-10 人
总部
Greenville,South Carolina
类型
私人持股
创立
2024
领域
Drug delivery、Sustained release、Deeper penetration into follicles和Enhanced bioavailability

地点

  • 主要

    141 Traction St.

    #2093

    US,South Carolina,Greenville,29611

    获取路线

Atticus Pharma员工

动态

  • 查看Atticus Pharma的公司主页,图片

    80 位关注者

    We’ve just created our LinkedIn page. Atticus Pharma, spun out of Zyl? Therapeutics earlier in 2024, now has a CEO (Leigh Hsu PhD/MBA) and a CMO (Dario Paggiarino MD), along with an Executive Chairman (Scott Pancoast) and a CFO (Charles Hinkle), both Harvard Business School alums from the early 80s. Look for exciting posts as Atticus leverages the patented Z-pod? sustained-release delivery system for topicals with novel drugs for lupus lesions and androgenic alopecia.

    Atticus Pharma | LinkedIn

    Atticus Pharma | LinkedIn

    linkedin.com

相似主页